Ocugen (OCGN) Cash & Equivalents (2014 - 2025)

Ocugen has reported Cash & Equivalents for 12 years, with the latest figure at $37.8 million in Q1 2025.

• For the quarter ending Q1 2025, Cash & Equivalents rose 43.18% year-over-year to $37.8 million; the trailing twelve-month figure through Mar 2025 stood at $37.8 million (up 43.18% YoY), and the FY2023 full-year result was $39.5 million, down 49.12% from the prior year.
• Cash & Equivalents for Q1 2025 stood at $37.8 million, up from $15.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $129.8 million in Q1 2022, with the low at $15.7 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $73.2 million across 5 years, with a median of $70.6 million in 2023.
• Annual changes were most pronounced in 2021 — Cash & Equivalents surged 1302.82% — and 2024, when it tumbled 77.76%.
• Ocugen's Cash & Equivalents stood at $95.0 million in 2021, then declined by 18.32% to $77.6 million in 2022, then plunged by 49.12% to $39.5 million in 2023, then plunged by 60.22% to $15.7 million in 2024, then surged by 140.81% to $37.8 million in 2025.
• The last three Cash & Equivalents figures came in at $37.8 million (Q1 2025), $15.7 million (Q2 2024), and $26.4 million (Q1 2024), per Business Quant data.